Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104130 · ClinicalTrials.gov registry record · Phase 2
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00104130 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 53 participants.
The verdict
NCT00104130, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
Interventions
- DRUG KOS-862
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104130
The ClinicalTrials.gov registry entry for NCT00104130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KOS-862 is the first listed.
NCT00104130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104130 about?
NCT00104130 is a clinical study titled "Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer". The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
What is the current status of trial NCT00104130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2004-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00104130?
The interventions under investigation include: KOS-862 (DRUG).
Who is sponsoring clinical trial NCT00104130?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.